temocillin: Clinical Trials

4 trials of temocillin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 not yet recruiting, 1 unknown. 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 34Completed 2, Not yet recruiting 1, Unknown 1

Follow temocillin: new trials by email Literature Review of temocillin trials Research Report on temocillin

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy of Temocillin Compared to Standard of Care in the Treatment of Neisseria Gonorrhoeae Infections
Temocillin (NEGABAN®) 2 g intravenous with lidocaine (3ml), Rectal swab for ESBL-E and microbiota (Eswab), Temocillin (NEGABAN®) 2 g intramuscular single dose with lidocaine (3ml) - Neisseria Gonorrhoeae (Ng) Infections
Phase 3Not yet recruitingAssistance Publique - Hôpitaux de Paris3602026-09-012026-06-22
Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit
Piperacillin/tazobactam or temocillin, Meropenem - Sepsis, Septic Shock
Phase 3UnknownAssistance Publique - Hôpitaux de Paris6002023-03-112023-04-18
Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins
Temocillin, Meropenem - Bacteremia
Phase 3CompletedFundación Pública Andaluza para la gestión de la Investigación en Sevilla3342020-12-152026-01-23
Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections
Temocillin, meropenem or imipenem - Urinary Tract Infections
Phase 3CompletedAssistance Publique - Hôpitaux de Paris292019-01-042025-11-20

Conditions studied

Infections (2)  ·  Bacteremia (1)  ·  Gonorrhea (1)  ·  Sepsis (1)  ·  Sexually Transmitted Diseases (1)  ·  Shock, Septic (1)  ·  Toxemia (1)  ·  Urinary Tract Infections (1)

Sponsors

Assistance Publique - Hôpitaux de Paris (3)  ·  Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1)

Countries

France (3)  ·  Spain (1)

Results publications

PMID 34580096, PMID 42425122

NIH funding

2017 (1), 2025 (1)